Literature DB >> 12815482

Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.

C C Barker1, J D Butzner, R A Anderson, R Brant, R S Sauve.   

Abstract

The incidence, risk factors and mortality of veno-occlusive disease (VOD) were identified for 142 pediatric hematopoietic stem cell (HSC) transplant recipients with hematological malignancies (83), solid tumors (41) and nonmalignant diseases (18). This historical cohort of 142 HSC transplant patients, from January 1993 through June 2000, was assessed by chart review. Risk factors for the development of VOD and mortality were assessed by multiple logistic regression and Kaplan-Meier survival curves respectively. The incidence of VOD was 18.3% (26/142 transplants). Multivariate analysis reconfirmed the known pretransplant risk factors of induction therapy with busulfan and transplantation with matched unrelated donor cells as significant risk factors for the development of VOD. In addition, two new risk factors, positive CMV serology in the recipient and TPN provided in the 30 days prior to transplant, were identified. Mortality in transplant patients at 100 days was greater in the VOD-positive group (10/26 (38.5%)) compared to the VOD-negative group (11/116 (9.5%) (P=0.001)). The risk of death was 4.97 times higher with 95% CIs (2.11, 11.71) for the VOD-positive group. Decreasing the risk factors for VOD may decrease mortality in this patient population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815482     DOI: 10.1038/sj.bmt.1704069

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  26 in total

1.  Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.

Authors:  Brandon M Triplett; Hani I Kuttab; Guolian Kang; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-14       Impact factor: 5.742

2.  The busulfan metabolite EdAG irreversibly glutathionylates glutaredoxins.

Authors:  Michele Scian; William M Atkins
Journal:  Arch Biochem Biophys       Date:  2015-08-14       Impact factor: 4.013

3.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

4.  Role of Initiating Supportive Care Preceding Veno-occlusive Disease Diagnosis Following Allogeneic Hematopoietic Stem Cell Transplantation in Children.

Authors:  Patricia Rayner; Jessica L Spruit; Roland Chu; Maxim Yankelevich; Meret Henry; Yaddanapudi Ravindranath; Süreyya Savaşan
Journal:  J Pediatr Hematol Oncol       Date:  2019-08       Impact factor: 1.289

Review 5.  Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2012-04-24

6.  The Myeloablative Drug Busulfan Converts Cysteine to Dehydroalanine and Lanthionine in Redoxins.

Authors:  Michele Scian; Miklos Guttman; Samantha D Bouldin; Caryn E Outten; William M Atkins
Journal:  Biochemistry       Date:  2016-08-11       Impact factor: 3.162

7.  Emergence of CD43-Expressing Hematopoietic Progenitors from Human Induced Pluripotent Stem Cells.

Authors:  Katharina U Kessel; Anika Bluemke; Hans R Schöler; Holm Zaehres; Peter Schlenke; Isabel Dorn
Journal:  Transfus Med Hemother       Date:  2017-05-29       Impact factor: 3.747

8.  Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.

Authors:  Joon Sup Song; Jong Jin Seo; Hyung Nam Moon; Thad Ghim; Ho Joon Im
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

9.  Fatal and unanticipated cardiorespiratory disease in a two-year-old child with hurler syndrome following successful stem cell transplant.

Authors:  Sampada Gupta; Anne O'Meara; Robert Wynn; Michael McDermott
Journal:  JIMD Rep       Date:  2013-03-09

Review 10.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.